[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cosmos Rx, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100647637","a-comparison-of-cosmos-rx-medication-adherence-platform-vs-pharmacy-fill-adherence-measures-100647637",false,"NCT07712614","A Comparison of Cosmos Rx Medication Adherence Platform vs. Pharmacy Fill Adherence Measures","A Comparison of Cosmos Rx Medication Adherence Platform (FORTISKAP™) vs. Pharmacy Fill Adherence Measures for Subjects Undergoing Treatment for Gastroesophageal Reflux Disease With Proton Pump Inhibitors","Inclusion Criteria:\n\nAge ≥ 21 years at time of enrollment Confirmed diagnosis of GERD and\u002For erosive esophagitis documented in the Epic medical record (ICD-10 code K21.0 or K21.9) Currently prescribed a once-daily oral PPI (omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, or dexlansoprazole) for a minimum of 30 days prior to enrollment Willing and able to fill PPI prescription exclusively at TidalHealth Community Pharmacy for the 90-day study period Owns a smartphone (iOS or Android) capable of running the FORTISKAP™ companion application Able to participate in the study enrollment and ongoing requirements in English.\n\nExclusion Criteria:\n\nCurrent diagnosis of active esophageal malignancy, gastric malignancy, or other upper gastrointestinal malignancy requiring active systemic treatment Cognitive impairment, dementia, or other neurological condition that, in the judgment of the Site PI, would prevent proper use of the FORTISKAP™ device or completion of self-report questionnaires Institutionalized subjects (nursing home, assisted living, correctional facility) or subjects whose medications are managed by a caregiver who would need to operate the device on their behalf Life expectancy \\\u003C 6 months in the judgment of the treating physician","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","Medication non-adherence is associated with greater morbidity and mortality in chronic disease, and has been estimated to increase healthcare costs by over $170 billion annually in the United States.1 Medication adherence is challenging for patients across the spectrum of medical disorders that are treated with long-term use of oral medications. Poor medication adherence can result in increased risk of complications, disease progression, increased healthcare utilization and poor therapeutic outcomes.2 Adherence is typically tracked using measures based on pharmacy fill data such as the medication possession ratio (MPR) and\u002For proportion of days covered (PDC).3 Although MPR and PDC are associated with a higher likelihood of using medication as prescribed at the population level, when compared to direct assessments or patient reports, they are not accurate enough for making individual management decisions and likely to underestimate non-adherence.4 However, real-time documentation methods using direct video observation are expensive and cumbersome for patients and providers.\n\nGastroesophageal reflux disease (GERD) is among the most prevalent gastrointestinal conditions in the United States, affecting an estimated 20-30% of the adult population.5 Proton pump inhibitors (PPIs) are the cornerstone of pharmacologic management for GERD forming the standard of care for erosive esophagitis, Barrett's esophagus, and symptomatic non-erosive reflux disease.6 Despite their established efficacy, suboptimal medication adherence remains a significant clinical barrier: estimates of PPI adherence in real-world populations range from 50-70% at one year7, with non-adherence associated with symptom recurrence, mucosal injury, and increased healthcare utilization.8 FORTISKAP™ (Cosmos Rx, Inc.) is a digital adherence monitoring device consisting of a sensor-embedded cap that attaches to standard prescription medication bottles. The device records the date and time of each bottle opening event and transmits this data wirelessly to a paired smartphone application, which generates adherence metrics and patient-facing reminders. Prescribers may access aggregated adherence data through a connected provider portal.\n\nThe goal of this study is to demonstrate that the Fortiskap™ prescription bottle-top, medication adherence device results in a higher detection rate of medication non-adherence compared to pharmacy fill-data assessment and\u002For compared to ARMS adherence self-assessment.",[26],"GERD (Gastroesophageal Reflux Disease)",[28],"proton pump inhibitor, GERD, medication adherence","NOT_YET_RECRUITING","2026-07-14",{"date":32,"type":33},"2026-07-17","ACTUAL",{"date":35,"type":20},"2026-09-01",{"date":37,"type":20},"2027-04-01",{"name":39,"class":40},"Cosmos Rx, Inc","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":41},"100637681","a-comparison-of-a-medication-adherence-platform-fortiskap-vs-usual-care-in-subjects-on-oral-medications-for-the-treatment-of-interstitial-lung-disease-sarcoid-and-pulmonary-hypertension-100637681","NCT07613216","A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension","Inclusion Criteria:\n\n1. 21 years of age or older at time of enrollment\n2. Primary diagnosis of interstitial lung disease (including sarcoidosis) AND\u002FOR pulmonary hypertension\n3. Currently managing their oral medications independently (i.e., without requiring caregiver administration)\n4. At least one oral medication with a primary indication for treatment of ILD or PH already in use, or planned for initiation with insurance approval secured, at the time of enrollment\n5. 6-Minute Walk Test (6MWT) scheduled within the next 30 days or performed within the past 30 days\n6. For ILD subjects: FVC and\u002For DLCO scheduled within the next 30 days or performed within the past 90 days\n7. For PH subjects: Cardiac echocardiography scheduled within the next 30 days or performed within the past 90 days\n8. Daily access to a smartphone compatible with the FORTISKAP™ companion application\n9. Proficient in English\n\nExclusion Criteria:\n\nFailure to meet any one of the above inclusion criteria","21 Years",{"count":50,"type":20},100,"OBSERVATIONAL","This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks prescription bottle openings and sends dose reminders to participants and their care team - take their medications more consistently and experience better health outcomes compared to similar participants receiving standard care without the device. Participation requires no changes to prescribed medications, testing or clinical visits beyond what is already part of routine care; participants use a modified medication bottle equipped with the FORTISKAP™ cap for nine months.",[54,55,56,57],"Idiopathic Pulmonary Fibrosis (IPF)","Sarcoidosis Lung","Pulmonary Hypertension","Usual Interstitial Pneumonia",[59,60,61,62],"medication adherence","Interstitial Lung Disease","nintedanib","pirfenidone","2026-05-26",{"date":65,"type":33},"2026-05-29",{"date":67,"type":20},"2026-07",{"date":69,"type":20},"2027-08",{"name":39,"class":40},""]